Nomic Bio, a pioneering protein profiling company, today announced the appointment of Byron Hewett to its board of directors. Hewett brings invaluable operational and strategic expertise to guide Nomic Bio through its crucial years of growth.
“We are thrilled to welcome Byron to Nomic’s board of directors as we commercialize and continue to scale our nELISA platform,” said Milad Dagher, CEO and co-founder of Nomic Bio. “Byron is a veteran in the tools space and his decades of experience and strategic insights will be instrumental during this next pivotal phase of growth.”
Mr. Hewett has more than 30 years of experience leading the development and commercialization of research and diagnostic tools. Most recently, he was CEO and Co-founder at Brava Diagnostics, focusing on point-of-care diagnostics. Previously, he was CEO of SomaLogic, a publicly listed proteomics company and Chairman and CEO of BioBehavioral Diagnostics, respectively. He was also CEO at Immunicon, and held senior roles at Qiagen, Bayer Diagnostics and Chiron Diagnostics.
“I have been following the progress of Nomic Bio for several years now and I’ve been quite impressed,” said Hewett. “Nomic’s nELISA platform addresses several of the industry’s bottlenecks in a scalable and versatile manner, and I look forward to collaborating with the team as we drive the company’s growth and expand its impact in the industry.”
The addition of Byron Hewett to Nomic Bio’s board of directors further solidifies the company’s position as a leader in the protein discovery space. Hewett will play a pivotal role in shaping the company’s strategic direction and accelerating its mission to revolutionize drug development and diagnostics.
